Clinical Trial

Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a Phase 4, prospective, open-label trial to evaluate the safety and effectiveness of sebetralstat when used for STP for a qualifying procedures in patients 12 years of age or older with hereditary angioedema (HAE).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-12.
Trial Details
NCT Number NCT07654829
Lead Sponsor KalVista Pharmaceuticals, Ltd.
Conditions Hereditary Angioedema
Enrollment 100 participants
Start Date 2026-07-31
Primary Completion 2027-11-29 (estimated)
Study Completion 2027-12-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-16